miRagen, Investigators from Goethe University and University Hospital Frankfurt and Servier Publish MRG-110 Phase 1 Pharmacodynamic Biomarker Data in Nucleic Acid Therapeutics

NEXT STORY
Broward Health Medical Center Becomes First Clinical Site in U.S. for Phase II Trial for LSALT Peptide
PREV STORY
Black Diamond Therapeutics Granted Fast Track Designation by the FDA for BDTX-189 for the Treatment of Adult Patients with a Solid Tumor Harboring an Allosteric HER2 Mutation or an EGFR or HER2 Exon 20 Insertion Mutation
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Five Prime Therapeutics Advances into Phase 1b Portion of Trial Evaluating the Immunotherapy Combination of Cabiralizumab (FPA008) and OPDIVO (nivolumab) in Multiple Tumor Types

Phase 1a/1b trial on track to enroll approximately 280 patientsPhase 1b portion of the ...

author_avatar
NASDAQ Market News

Sunshine Biopharma Receives $0.9 Million in Additional Funding From RB Capital

author_avatar
NASDAQ Market News

Dynavax to Present at the Cowen & Co. Annual Health Care Conference

BERKELEY, Calif., March 05, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) announced today ...

author_avatar
NASDAQ Market News